WO2007117600A3 - Combination therapy for treating autoimmune diseases - Google Patents

Combination therapy for treating autoimmune diseases Download PDF

Info

Publication number
WO2007117600A3
WO2007117600A3 PCT/US2007/008579 US2007008579W WO2007117600A3 WO 2007117600 A3 WO2007117600 A3 WO 2007117600A3 US 2007008579 W US2007008579 W US 2007008579W WO 2007117600 A3 WO2007117600 A3 WO 2007117600A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
cell
autoimmune diseases
treating autoimmune
modulating
Prior art date
Application number
PCT/US2007/008579
Other languages
French (fr)
Other versions
WO2007117600A2 (en
Inventor
Scott Koenig
Original Assignee
Macrogenics Inc
Scott Koenig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Scott Koenig filed Critical Macrogenics Inc
Publication of WO2007117600A2 publication Critical patent/WO2007117600A2/en
Publication of WO2007117600A3 publication Critical patent/WO2007117600A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Abstract

A combination therapy comprising administering to a subject in need of an effective therapeutic treatment for an autoimmune disease, a T cell antibody that is capable of modulating the activation of a T cell response to an antigen presenting cell in combination with a B cell antibody. The combination therapy may provide improved clinical benefits to a subject in need of treatment by reducing the circulating and tissue levels of B cells while providing immunosuppression of T cell activation, thus modulating the immune response to self antigens.
PCT/US2007/008579 2006-04-07 2007-04-06 Combination therapy for treating autoimmune diseases WO2007117600A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78989906P 2006-04-07 2006-04-07
US60/789,899 2006-04-07
US84409506P 2006-09-13 2006-09-13
US60/844,095 2006-09-13

Publications (2)

Publication Number Publication Date
WO2007117600A2 WO2007117600A2 (en) 2007-10-18
WO2007117600A3 true WO2007117600A3 (en) 2008-08-14

Family

ID=38581644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008579 WO2007117600A2 (en) 2006-04-07 2007-04-06 Combination therapy for treating autoimmune diseases

Country Status (1)

Country Link
WO (1) WO2007117600A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
SG163615A1 (en) 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2655080A1 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2012103365A1 (en) * 2011-01-28 2012-08-02 Oregon Health & Science University Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
PT2714733T (en) 2011-05-21 2019-05-23 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
PL2953972T3 (en) 2013-02-05 2021-03-08 Engmab Sàrl Method for the selection of antibodies against bcma
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2016130950A1 (en) * 2015-02-12 2016-08-18 The Regents Of The University Of Michigan Anti-kir antibodies
EA202092435A3 (en) 2015-08-03 2021-06-30 Энгмаб Сарл MONOCLONAL ANTIBODIES AGAINST BCMA
PE20180795A1 (en) 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THE USE OF THEM
JP7002467B2 (en) 2016-04-15 2022-01-20 マクロジェニクス，インコーポレーテッド New B7-H3 binding molecule, its antibody drug conjugate, and how to use it
MX2018016404A (en) 2016-06-21 2019-10-15 Teneobio Inc Cd3 binding antibodies.
CN109843325B (en) 2016-09-14 2023-10-03 特尼奥生物股份有限公司 CD3 binding antibodies
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2018119215A1 (en) 2016-12-21 2018-06-28 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
WO2020252366A1 (en) 2019-06-14 2020-12-17 Teneobio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CN115666727A (en) 2020-05-19 2023-01-31 詹森生物科技公司 Compositions comprising a T cell redirecting therapeutic agent and a VLA-4 adhesion pathway inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease
US20050037004A1 (en) * 2001-09-26 2005-02-17 Isis Innovation Limited Treatment of chronic joint inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease
US20050037004A1 (en) * 2001-09-26 2005-02-17 Isis Innovation Limited Treatment of chronic joint inflammation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
WO2007117600A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2007117600A3 (en) Combination therapy for treating autoimmune diseases
NZ591362A (en) Multiple-variable dose regimen for treating tnfa-related disorders
WO2007136518A3 (en) Treatment of autoimmune disorders
WO2007092939A8 (en) Antigenic gm-csf peptides and antibodies to gm-csf
WO2013088148A3 (en) Method of treatment employing therapeutic t cell product from mobilised donors
EA200901211A1 (en) ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2007053661A3 (en) Uses of anti-cd40 antibodies
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
RS20150135A1 (en) Treatment with anti-vegf antibodies
EA201001695A1 (en) APPLICATION OF EPOTHILON D FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TAU-PROTEIN
WO2008140855A3 (en) Therapeutic device incorporating light and cold therapy modalities
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
MX2016000220A (en) Regulation of glucose metabolism using anti-cgrp antibodies.
WO2010054377A3 (en) Fully human antibodies against n-cadherin
EA201171352A1 (en) ANTIGENSAGING ANTIBODY FRAGMENTS AND THEIR APPLICATION FOR THE TREATMENT OR DIAGNOSTICS OF EYE DISEASES
WO2007002571A3 (en) Use of an anti c5 complement antibody to treat patients with sickle cell disease
CN205084203U (en) Spontaneous heating traditional chinese medicine health care binder
WO2007011960A3 (en) Methods and agents to treat autoimmune diseases
WO2005072292A3 (en) Methods for enhancing radiation therapy
CN204070763U (en) Magnetic therapy shoe
Kato et al. Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation
Alukov et al. Principles of intensive treatment of pancreonecrosis
Katram Dr. Antapur Venkoba Rao

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07774856

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07774856

Country of ref document: EP

Kind code of ref document: A2